ASXL1 and acute myeloid leukemia: Additional pathogenic variants included DNMT3A, TET2, ASXL1, JAK2, and SH2B3. All three patients were treated with AML-directed therapy (decitabine/venetoclax or liposomal cytarabine/daunorubicin).